Netomnia and Adtran deploy UK’s first commercial 50G PON service
22.5.2025 15:00:00 EEST | Business Wire | Press release
Adtran and Netomnia today announced a major milestone in the evolution of the UK’s broadband market with the first-ever commercial deployment of a 50G PON service. Netomnia is using Adtran’s SDX 6400 Series to upgrade an existing residential customer with an ultra-high-speed service. The deployment is the first of its kind in the UK and will provide real-world insight into how providers can leverage next-generation PON technology to meet growing demand for ultra-high-speed connectivity. The flexibility of Adtran’s SDX 6400 Series enabled Netomnia to easily deploy the service alongside existing PON technologies with no interruption.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250522308716/en/
Adtran’s SDX 6400 Series helped Netomnia deploy the UK’s first commercial 50G PON service.
“At Netomnia, we’re building a fiber network for whatever comes next — and with the UK’s first commercial 50G PON deployment, we’re proving it,” said Jeremy Chelot, Group CEO of Netomnia, YouFibre and brsk. “This isn’t just about speed; it’s about power. From AI-driven smart homes to lag-free metaverse experiences and tomorrow’s enterprise demands, we’re making sure the most powerful internet lives on our network. Partnering with Adtran, we’re redefining what fiber can deliver — no compromises, no limits, just the future delivered.”
Netomnia, the UK’s second-largest alternative network provider, now serves 2.4 million premises, with YouFibre and brsk connecting 310,000 customers. With an annual build rate of one million premises, the group is on track to reach five million serviceable premises by 2027. Together, Netomnia, YouFibre and brsk have secured £1.5 billion in funding, reinforcing their position as one of the UK’s most scalable and capital-efficient retail, wholesale and consolidation platforms.
The deployment uses Adtran’s SDX 6400 Series, a modular, software-defined OLT platform engineered for high-density environments and advanced service delivery. The solution enables providers to deliver ultra-high-capacity services while seamlessly coexisting with already deployed PON networks. The system’s disaggregated architecture supports open interfaces and network automation, while its energy-efficient, compact design helps operators meet sustainability goals. By delivering 50G PON rates over existing fiber infrastructure, the deployment demonstrates how 50G PON can support future residential services, enterprise access, mobile transport and emerging smart city applications.
“We committed to Netomnia in 2024 that they would be the first provider in the UK to deploy a commercial 50G PON solution. Today, we achieved that milestone, helping them deliver a live ultra-high-speed service to an existing customer,” commented Stuart Broome, GM of EMEA sales at Adtran. “The deployment demonstrates how our SDX 6400 Series empowers operators to scale capacity, accelerate service delivery and support next-generation applications, all while leveraging their existing infrastructure. As demand surges for bandwidth-intensive services like generative AI, 5G backhaul and enterprise connectivity, this project shows how we’re helping partners like Netomnia stay ahead of the curve.”
Further information on the SDX 6400 Series is available in this video.
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the majority shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
About Netomnia
Netomnia is a wholesale fibre operator, the UK's fourth-largest full-fibre network. With an ambitious rollout plan to reach 5 million premises by 2027, backed by over £1.5 billion in funding, we are building an uncompromising, capital-efficient fibre network that delivers tomorrow’s innovations today. The Netomnia network is where the most powerful internet lives, redefining what’s possible for businesses and communities across the UK. For more information visit: netomnia.com.
Published by
ADTRAN Holdings, Inc.
www.adtran.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250522308716/en/
Contacts
For media
Gareth Spence
+44 1904 699 358
public.relations@adtran.com
For investors
Peter Schuman
+1 256 963 6305
investor.relations@adtran.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom